Oxidative polymorphism of dextromethorphan in a Burundi population

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Clinical Pharmacology

Background:

• Dextromethorphan (DMP) is widely available, safe, and metabolized by cytochrome P450 enzymes, similar to debrisoquine.
• These characteristics make DMP a preferred test substance for assessing oxidation phenotypes in clinical pharmacology studies.
• Understanding individual metabolic profiles is crucial for personalized medicine and drug efficacy.

Purpose of the Study:

• To determine the prevalence of poor metabolizers within a healthy Burundian population.
• To evaluate the utility of dextromethorphan as a test substance for phenotyping in this specific demographic.
• To assess the feasibility of using Thin-Layer Chromatography (TLC) for large-scale phenotyping studies.

Main Methods:

• 100 healthy Burundian volunteers (94 males, 6 females) ingested 50 mg DMP hydrobromide (38.5 mg DMP base).
• Urine samples were collected over an 8-hour period post-administration.
• Thin-Layer Chromatography (TLC) was employed for the analysis of urine samples to determine DMP metabolic profiles.

Main Results:

• The study identified 5% of the Burundian subjects as poor metabolizers.
• The TLC method proved to be cost-effective, rapid, and suitable for analyzing a large cohort.
• This highlights a significant prevalence of CYP2D6 poor metabolizers in the studied population.

Conclusions:

• Dextromethorphan is a suitable and practical agent for phenotyping oxidation status in diverse populations.
• The prevalence of poor metabolizers in the Burundian cohort is 5%, indicating potential implications for drug therapy.
• The employed TLC method is efficient for large-scale pharmacogenetic research.